The global biopharmaceutical contract manufacturing market size was worth USD 6.55 billion in 2021. It is further expected to rise at a CAGR of 9.10% and value USD 10.12 billion by 2026.
MARKET DRIVERS:
The global biopharmaceutical contract manufacturing market is majorly driven by the faster pace of production with contract manufacturing organizations, less cost compared to own manufacturing facilities, entry-level pharmaceutical production companies looking for investors. Additionally, faster approvals for patent sharing, intellectual property copyright rules, higher demand for the drugs by the people, less production capacity, etc., are expected to promote the growth rate of the biopharmaceutical contract manufacturing market. Actually, any big pharma giant cannot manufacture every single drug on their own, so they opt for contractual obligations with small companies to produce drugs by entering with an MOU or by investments in the production.
There are a lot of budding entries in the field of CMOs in all these recent years. This has provided the key pharmaceutical manufacturers an opportunity to reduce the burden of manufacturing every new drug on their own. Pharma industries see this as an opportunity to reduce their investments in manufacturing by going for outsourcing to these organizations. Due to this, the amount spent on manufacturing can be diverted to the R&D division for efficient drug inventions. For CMOs, there is an opportunity with the biopharmaceutical contract manufacturing market expansion in the form of Mergers, acquisitions, and joint ventures with the big companies. These actions make the CMOs realize the opportunities to make their organizations financially stable and technologically capable.
MARKET RESTRAINTS:
There are few restraints for the global biopharmaceutical contract manufacturing market to expand as the small companies lack technological experience in manufacturing the biopharmaceutical manufacturing, abuse of patent sharing details, easy reverse engineering of the drug composition formula, etc., are restraining the market for further expansion. These factors provoke the pharma giants to install their own production facilities with huge investments undermining the efficacy of Contract manufacturing organizations (CMOs).
Major challenges faced by the key market players are lack of technological capabilities of small companies, lack of strategic management of resources, and lack of quality oversight. Due to these factors, many big companies are opting for in-house production facilities to manufacture biopharmaceutical products. This poses a threat to the expansion of CMOs for further expansion. Lack of intellectual property rules in many countries and unbridled patent rights in some countries are also posing challenges for the market growth of contract manufacturing organizations.
COVID-19 impact on the global biopharmaceutical contract manufacturing market:
Biopharmaceutical companies are on the frontline, working to innovate more products to treat the patients infected with covid 19. Many companies are in the journey of genome sequencing and inventing a viable vaccine candidate for the covid 19. Many oral drugs and intravenous drugs are being administered to the patients on a large scale. Such demand cannot be met by the key manufacturing players alone, so there is an increase in contractual terms with small players driving the supply and expanding the market. So, all these biotech entities are striving to investigate the virus and its strains; many investments are diverted to big and small companies.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Product Type, Therapeutic Area, Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global biopharmaceutical contract manufacturing market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.
Biopharmaceutical Contract Manufacturing Market – By Product Type:
Of all these segments, vaccines and insulin segments lead the way as these are used in inhibiting diabetes and other seasonal cases of flu.
Biopharmaceutical Contract Manufacturing Market – By Therapeutic Area:
Out of all these segments, oncological and cardiovascular disease-related segments lead the market as many pharma companies outsource their oncological drug production to different companies.
Biopharmaceutical Contract Manufacturing Market – By Application:
Based on the application, the clinical application market segment registers the highest growth in biopharmaceutical pharma production.
Biopharmaceutical Contract Manufacturing Market – By Region:
Geographically, North America is the leading market for the contract manufacturing of biopharmaceutical products. This can be attributed to the large-scale investments in CMOs and better intellectual property rights-related laws. The North American region takeovers the global market largely based on market collaborations and agreements, as key business strategies lead to growth and expansion worldwide. Such large organizations also buy minor-scale biopharmaceutical companies in the Asia Pacific region to reinforce their market presence. The Oncology area is witnessing a large growth owing to an increase in cancer-related diseases. The market has also observed growth in Research and Development and a surge in innovative developments in manufacturing.
KEY MARKET PARTICIPANTS:
Noteworthy companies operating in the global biopharmaceutical contract manufacturing market profiled in this report are Patheon N.V., Rentschler Biotechnologie GmbH, AbbVie Contract Manufacturing (An AbbVie Company), Biomeva GmbH, Boehringer Ingelheim GmbH, WuXi Biologics, Abzena Plc, Lonza Group AG, Probiogen AG, Sandoz International GmbH, Fujifilm Diosynth Biotechnologies, KBI Biopharma, Inc., Cytovance Biologics, Inc., Baxter Biopharma Solutions, Vetter Pharma International GmbH, Catalent, Inc., Samsung Biologics Co., Ltd. and Ajinomoto Althea, Inc.
Growing pharmaceutical development is offering lucrative opportunities for the contractual manufacturing organizations to prosper in the segment. Recently, the AstraZeneca vaccine for COVID-19 has entered into a partnership with Serum Institute of India for manufacturing the vaccine; SII has entered into three other Indian firms for manufacturing the vaccines. Russian vaccine giant gamaleya research institute tied up with Dr. Reddy's laboratories for manufacturing of sputnik vaccine. These kinds of agreements are taking place at a large scale due to the increase in the usage of biologics in the field.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Growth Factors
5.1.5 Interferons
5.1.6 Recombinant Protiens
5.1.7 Vaccines
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Product Type
5.1.10 Market Attractiveness Analysis, By Product Type
5.1.11 Market Share Analysis, By Product Type
5.2 Therapeutic Area
5.2.1 Introduction
5.2.2 Infectious Disease
5.2.3Cardiovascular Disease
5.2.4 Oncology
5.2.5 Metabolic Disease
5.2.6 Respiratory Disorder
5.2.7 Autoimmune Disease
5.2.8 Neurology
5.2.9 Ophthalmology
5.2.10 Others
5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area
5.2.12 Market Attractiveness Analysis, By Therapeutic Area
5.2.13 Market Share Analysis, By Therapeutic Area
5.3 Application
5.3.1 Introduction
5.3.2 Clinical
5.3.3 Commercial
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Therapeutic Area
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Therapeutic Area
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Therapeutic Area
6.1.5.4 By Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Patheon N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2Rentschler Biotechnologie GmbH
8.3 AbbVie Contract Manufacturing (An AbbVie Company)
8.4 Biomeva GmbH
8.5 Boehringer Ingelheim GmbH
8.6 WuXi Biologics
8.7 Abzena Plc
8.8 Lonza Group AG
8.9 Samsung Biologics Co.
8.10 Ajinomoto Althea, Inc.
8.11 Fujifilm Diosynth Biotechnologies
8.12 Probiogen AG
8.13 Sandoz International GmbH
8.14 KBI Biopharma, Inc.
8.15 Baxter Biopharma Solutions
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
